Featured Content:
March 21, 2010
A new study by University of Alabama at Birmingham (UAB) researchers shows that body-mass index (BMI) and co-existing medical conditions (co-morbidity) do not explain the decreased survival observed among African-Americans compared to Caucasians who also have colon cancer. The study is published online Nov. 23 in Cancer, a journal of the American Cancer Society. (Source: Health News from Medical News Today) Go to Source… Continue reading
March 21, 2010
The New York Times recounts the steps Democrats took to regroup on the health overhaul legislation after losing their filibuster proof majority in the Senate after Massachusetts voters elected Republican Scott Brown in January. According to the Times account, House Speaker Nancy Pelosi helped steer President Barack Obama away from a more modest approach on health care. ‘“We’re in the majority,’ Ms. Pelosi told the president. ‘We’ll never have a better majority in your presidency in numbers than we’ve got right now. We can make this work,” the paper reported.”Now, in what could become a legislative Lazarus tale — or… Continue reading
March 21, 2010
Prader-Willi syndrome, also known as PWS is an uncommon genetic disorder (present at birth) in which seven genes (or subsets) on chromosome 15 are deleted or unexpressed. Patients with PWS may have physical, mental and behavioral problems – the main one being an unrelenting feeling of hunger.
Individual with Prader-Willi syndrome have serious problems controlling their body weight, because they spend much longer eating than other people do – there is a very strong food compulsion. PWS is the most common genetic cause of morbid obesity in children.
According to the Prader-Willi Association, USA, between 1 in 8,000 and 1 in 25,000… Continue reading
March 21, 2010
The U.S. Department of Health and Human Services and the U.S. Centers for Disease Control and Prevention announced today that Public Health – Seattle & King County has been awarded two highly-competitive federal stimulus grants totaling $25.5 million dollars over two years to address obesity and tobacco use, two of the leading contributors to premature illness, death and health care costs in the United States and locally.
“It’s a huge credit to our Public Health staff and partners that we were able to get such a competitive grant to improve our community’s health,” said King County Executive Dow Constantine. Over 600… Continue reading
March 21, 2010
Boston has received $12.5 million in federal stimulus funding for a sweeping new effort to combat obesity and reduce smoking, Mayor Thomas M. Menino said yesterday.
Menino said the money, which would be spent over a two-year period, would be “a significant down payment on making Boston the healthiest city in America.’’
The city has a goal of reducing obesity rates by 20 and 30 percent in adults and children. respectively, over the next five years, and closing the gap between blacks and Latinos and whites. Go to Source… Continue reading
March 21, 2010
The U.S. Department of Health and Human Services is trying to combat the obesity problem by distributing over 372 million dollars in grants. Some of that money is being sent right here to Douglas County.
While a study shows obesity becoming more of a problem across the country, the stats in Douglas Country don’t paint a great picture either.
When it comes to the Omaha youth, the numbers become even more disturbing. But thanks to a 5.7 million dollar grant, Omahans will have a better chance to fight this problem head on. Go to Source… Continue reading
March 21, 2010
Emisphere Technologies, Inc. (OTCBB:EMIS) and Alchemia Ltd. (ASX:ACL) announced that they are joining efforts to develop an oral formulation of the anti-coagulant drug fondaparinux with Emisphere’s Eligen® Technology. Emisphere’s broad-based drug delivery platform, known as the Eligen® Technology, uses proprietary, synthetic carriers to enhance the oral bioavailability of a drug without altering its chemical form or biological activity. Fondaparinux, an anti-coagulant used for the prevention of deep vein thrombosis, is marketed in injectable form as Arixtra® by GlaxoSmithKline…
Go to Source… Continue reading
March 21, 2010
Emisphere Technologies, Inc. (OTCBB:EMIS) and Alchemia Ltd. (ASX:ACL) announced that they are joining efforts to develop an oral formulation of the anti-coagulant drug fondaparinux with Emisphere’s Eligen® Technology. Emisphere’s broad-based drug delivery platform, known as the Eligen® Technology, uses proprietary, synthetic carriers to enhance the oral bioavailability of a drug without altering its chemical form or biological activity. Fondaparinux, an anti-coagulant used for the prevention of deep vein thrombosis, is marketed in injectable form as Arixtra® by GlaxoSmithKline…
Go to Source… Continue reading
